{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:53:36Z","timestamp":1791219216998,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82304456"],"award-info":[{"award-number":["82304456"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-060"],"award-info":[{"award-number":["2022-PUMCH-B-060"]}]},{"name":"Peking Union Medical College Hospital Outstanding Young Talent Development Program","award":["UBJ11756"],"award-info":[{"award-number":["UBJ11756"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["CIFMS 2021-I2M-1-003"],"award-info":[{"award-number":["CIFMS 2021-I2M-1-003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01962-y","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T01:42:30Z","timestamp":1765417350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical characteristics and treatment patterns of systemic sclerosis patients in China: a single-center retrospective study"],"prefix":"10.1007","volume":"26","author":[{"given":"Xin","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"1962_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.semarthrit.2016.12.003","volume":"46","author":"RE Pellar","year":"2017","unstructured":"Pellar RE, Pope JE. Evidence-based management of systemic sclerosis: navigating recommendations and guidelines. Semin Arthritis Rheum. 2017;46:767\u201374.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1962_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.berh.2018.08.005","volume":"32","author":"F Ingegnoli","year":"2018","unstructured":"Ingegnoli F, Ughi N, Mihai C. Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. Best Pract Res Clin Rheumatol. 2018;32(2):223\u201340.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1962_CR3","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202\u20135.","journal-title":"J Rheumatol"},{"key":"1962_CR4","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685\u201399.","journal-title":"Lancet"},{"key":"1962_CR5","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1093\/rheumatology\/keab190","volume":"60","author":"M Bairkdar","year":"2021","unstructured":"Bairkdar M, Rossides M, Westerlind H, Hesselstrand R, Arkema EV, Holmqvist M. Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology (Oxford). 2021;60:3121\u201333.","journal-title":"Rheumatology (Oxford)"},{"key":"1962_CR6","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/rheumatology\/key139","volume":"57","author":"DH Dougherty","year":"2018","unstructured":"Dougherty DH, Kwakkenbos L, Carrier ME, et al. The scleroderma patient-centered intervention network cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology (Oxford). 2018;57:1623\u201331.","journal-title":"Rheumatology (Oxford)"},{"key":"1962_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1867-1","volume":"21","author":"MR Pokeerbux","year":"2019","unstructured":"Pokeerbux MR, Giovannelli J, Dauchet L, et al. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Res Ther. 2019;21:86.","journal-title":"Arthritis Res Ther"},{"key":"1962_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01733-4","volume":"16","author":"A Coi","year":"2021","unstructured":"Coi A, Barsotti S, Santoro M, et al. Epidemiology of systemic sclerosis: a multi-database population-based study in Tuscany (Italy). Orphanet J Rare Dis. 2021;16:90.","journal-title":"Orphanet J Rare Dis"},{"key":"1962_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"AT Masi","year":"1980","unstructured":"Masi AT. Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthr Rheum. 1980;23:581\u201390.","journal-title":"Arthr Rheum"},{"key":"1962_CR10","first-page":"1747","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of Rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum. 2013;72:1747\u201355.","journal-title":"Arthritis Rheum"},{"key":"1962_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02699-1","volume":"18","author":"H He","year":"2023","unstructured":"He H, Lai J, Zhou J, et al. The clinical characteristics and outcomes of patients with systemic sclerosis with myocardial involvement. Orphanet J Rare Dis. 2023;18:83.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1962_CR12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3109\/03009742.2016.1153141","volume":"45","author":"A Santosa","year":"2016","unstructured":"Santosa A, Tan CS, Teng GG, et al. Lung and gastrointestinal complications are leading causes of death in SCORE, a multi-ethnic Singapore systemic sclerosis cohort. Scand J Rheumatol. 2016;45(6):499\u2013506.","journal-title":"Scand J Rheumatol"},{"key":"1962_CR13","doi-asserted-by":"publisher","first-page":"e0163894","DOI":"10.1371\/journal.pone.0163894","volume":"11","author":"VK Jaeger","year":"2016","unstructured":"Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: A longitudinal EUSTAR study. PLoS ONE. 2016;11:e0163894.","journal-title":"PLoS ONE"},{"key":"1962_CR14","doi-asserted-by":"publisher","first-page":"7062","DOI":"10.3748\/wjg.v19.i41.7062","volume":"19","author":"XP Tian","year":"2013","unstructured":"Tian XP, Zhang X. Gastrointestinal complications of systemic sclerosis. World J Gastroenterol. 2013;19:7062\u20138.","journal-title":"World J Gastroenterol"},{"key":"1962_CR15","doi-asserted-by":"crossref","unstructured":"Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990;113:352\u20137.","DOI":"10.7326\/0003-4819-113-5-352"},{"key":"1962_CR16","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/1756-185X.13905","volume":"23","author":"J Zhou","year":"2020","unstructured":"Zhou J, Hou Y, Wang Q, Li M, Zeng X, Xu D. Clinical features and long-term outcomes of Chinese patients with scleroderma renal crisis. Int J Rheum Dis. 2020;23:1194\u2013200.","journal-title":"Int J Rheum Dis"},{"key":"1962_CR17","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.3899\/jrheum.120283","volume":"39","author":"M Vanthuyne","year":"2012","unstructured":"Vanthuyne M, Smith V, De Langhe E, et al. The Belgian systemic sclerosis cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile. J Rheumatol. 2012;39:2127\u201333.","journal-title":"J Rheumatol"},{"key":"1962_CR18","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","volume":"71","author":"FM Meier","year":"2012","unstructured":"Meier FM, Frommer KW, Dinser R, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2012;71:1355\u201360.","journal-title":"Ann Rheum Dis"},{"key":"1962_CR19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.semarthrit.2011.10.004","volume":"41","author":"CP Sime\u00f3n-Aznar","year":"2012","unstructured":"Sime\u00f3n-Aznar CP, Fonollosa-Pl\u00e1 V, Tolosa-Vilella C, et al. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status. Semin Arthritis Rheum. 2012;41:789\u2013800.","journal-title":"Semin Arthritis Rheum"},{"key":"1962_CR20","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3899\/jrheum.171443","volume":"45","author":"KW Moon","year":"2018","unstructured":"Moon KW, Lee SS, Lee YJ, et al. Clinical and laboratory characteristics and mortality in Korean patients with systemic sclerosis: a nationwide multicenter retrospective cohort study. J Rheumatol. 2018;45:1281\u20138.","journal-title":"J Rheumatol"},{"key":"1962_CR21","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s10067-021-05997-w","volume":"41","author":"R Freitas","year":"2022","unstructured":"Freitas R, Martins P, Dourado E, et al. Gender differences in clinical features and outcomes of a Portuguese systemic sclerosis cohort. Clin Rheumatol. 2022;41:1139\u201344.","journal-title":"Clin Rheumatol"},{"key":"1962_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102494","volume":"19","author":"M Hughes","year":"2020","unstructured":"Hughes M, Pauling JD, Armstrong-James L, Denton CP, Galdas P, Flurey C. Gender-related differences in systemic sclerosis. Autoimmun Rev. 2020;19:102494.","journal-title":"Autoimmun Rev"},{"key":"1962_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1046\/j.1365-2249.1999.00961.x","volume":"117","author":"H Ihn","year":"1999","unstructured":"Ihn H, Yamane K, Yazawa N, et al. Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. Clin Exp Immunol. 1999;117:383\u20137.","journal-title":"Clin Exp Immunol"},{"key":"1962_CR24","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1136\/annrheumdis-2013-204487","volume":"74","author":"P Moinzadeh","year":"2015","unstructured":"Moinzadeh P, Aberer E, Ahmadi-Simab K, et al. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2015;74:730\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1962_CR25","first-page":"104","volume":"34","author":"OC Meyer","year":"2007","unstructured":"Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol. 2007;34:104\u20139.","journal-title":"J Rheumatol"},{"key":"1962_CR26","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3899\/jrheum.111582","volume":"39","author":"PD Sampaio-Barros","year":"2012","unstructured":"Sampaio-Barros PD, Bortoluzzo AB, Marangoni RG, et al. Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients. J Rheumatol. 2012;39:1971\u20138.","journal-title":"J Rheumatol"},{"key":"1962_CR27","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/rheumatology\/ken179","volume":"47","author":"N Hunzelmann","year":"2008","unstructured":"Hunzelmann N, Genth E, Krieg T, et al. The registry of the German network for systemic scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford). 2008;47:1185\u201392.","journal-title":"Rheumatology (Oxford)"},{"key":"1962_CR28","first-page":"1","volume":"1","author":"S Ghosh","year":"2023","unstructured":"Ghosh S, Tanna D, Telang K, Dhuria S, Gupta R. Clinical and autoantibody profiles of systemic sclerosis patients: a cross-sectional study from North India. Indian J Dermatol Venereol Leprol. 2023;1:1\u20137.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1962_CR29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/1756-185X.12322","volume":"18","author":"I Sujau","year":"2015","unstructured":"Sujau I, Ng CT, Sthaneshwar P, et al. Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort. Int J Rheum Dis. 2015;18:459\u201365.","journal-title":"Int J Rheum Dis"},{"key":"1962_CR30","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.3899\/jrheum.100298","volume":"38","author":"A Hashimoto","year":"2011","unstructured":"Hashimoto A, Tejima S, Tono T, et al. Predictors of survival and causes of death in Japanese patients with systemic sclerosis. J Rheumatol. 2011;38:1931\u20139.","journal-title":"J Rheumatol"},{"key":"1962_CR31","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10067-012-2145-7","volume":"32","author":"J Wang","year":"2013","unstructured":"Wang J, Assassi S, Guo G, et al. Clinical and serological features of systemic sclerosis in a Chinese cohort. Clin Rheumatol. 2013;32:617\u201321.","journal-title":"Clin Rheumatol"},{"key":"1962_CR32","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/1756-185X.13859","volume":"23","author":"C Foocharoen","year":"2020","unstructured":"Foocharoen C, Peansukwech U, Mahakkanukrauh A, et al. Clinical characteristics and outcomes of 566 Thais with systemic sclerosis: a cohort study. Int J Rheum Dis. 2020;23:945\u201357.","journal-title":"Int J Rheum Dis"},{"key":"1962_CR33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/art.30159","volume":"63","author":"E Hsu","year":"2011","unstructured":"Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Feghali-Bostwick CA. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 2011;63:783\u201394.","journal-title":"Arthritis Rheum"},{"key":"1962_CR34","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3899\/jrheum.151353","volume":"43","author":"M Turk","year":"2016","unstructured":"Turk M, Pope JE. The frequency of scleroderma renal crisis over time: a meta analysis. J Rheumatol. 2016;43:1350\u20135.","journal-title":"J Rheumatol"},{"key":"1962_CR35","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard.2006.062901","volume":"66","author":"UA Walker","year":"2007","unstructured":"Walker UA, Tyndall A, Czirj\u00e1k L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2007;66:754\u201363.","journal-title":"Ann Rheum Dis"},{"key":"1962_CR36","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/rheumatology\/key350","volume":"58","author":"N Richard","year":"2019","unstructured":"Richard N, Hudson M, Wang M, et al. Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. Rheumatology (Oxford). 2019;58:636\u201344.","journal-title":"Rheumatology (Oxford)"},{"key":"1962_CR37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1586\/1744666X.2016.1115717","volume":"12","author":"MO Becker","year":"2016","unstructured":"Becker MO, Riemekasten G. Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. Expert Rev Clin Immunol. 2016;12:115\u201335.","journal-title":"Expert Rev Clin Immunol"},{"key":"1962_CR38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11926-011-0217-3","volume":"14","author":"G Gyger","year":"2012","unstructured":"Gyger G, Baron M. Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep. 2012;14:22\u20139.","journal-title":"Curr Rheumatol Rep"},{"key":"1962_CR39","first-page":"2218","volume":"34","author":"M Hudson","year":"2007","unstructured":"Hudson M, Walker JG, Fritzler M, Taillefer S, Baron M. Hypocomplementemia in systemic sclerosis\u2013clinical and serological correlations. J Rheumatol. 2007;34:2218\u201323.","journal-title":"J Rheumatol"},{"key":"1962_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1147-2","volume":"18","author":"J Esposito","year":"2016","unstructured":"Esposito J, Brown Z, Stevens W, et al. The association of low complement with disease activity in systemic sclerosis: a prospective cohort study. Arthritis Res Ther. 2016;18:246.","journal-title":"Arthritis Res Ther"},{"key":"1962_CR41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS): endorsed by: association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT). Eur Heart J. 2016;37:67\u2013119.","journal-title":"Eur Heart J"},{"key":"1962_CR42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1183\/09031936.00074309","volume":"35","author":"SC Mathai","year":"2010","unstructured":"Mathai SC, Bueso M, Hummers LK, et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J. 2010;35:95\u2013104.","journal-title":"Eur Respir J"},{"key":"1962_CR43","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/resp.14609","volume":"29","author":"CJW Stock","year":"2024","unstructured":"Stock CJW, Bray WG, Kouranos V, et al. Serum C-reactive protein is associated with earlier mortality across different interstitial lung diseases. Respirology. 2024;29:228\u201334.","journal-title":"Respirology"},{"key":"1962_CR44","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jacc.2008.12.038","volume":"53","author":"R Quarck","year":"2009","unstructured":"Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;53:1211\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1962_CR45","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","volume":"401","author":"ER Volkmann","year":"2023","unstructured":"Volkmann ER, Andr\u00e9asson K, Smith V. Systemic sclerosis. Lancet. 2023;401:304\u201318.","journal-title":"Lancet"},{"key":"1962_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152228","volume":"62","author":"R Dziedzic","year":"2023","unstructured":"Dziedzic R, W\u00f3jcik K, Olchawa M, et al. Increased oxidative stress response in circulating blood of systemic sclerosis patients - relation to disease characteristics and inflammatory blood biomarkers. Semin Arthritis Rheum. 2023;62:152228.","journal-title":"Semin Arthritis Rheum"},{"key":"1962_CR47","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3899\/jrheum.180582","volume":"47","author":"P Moinzadeh","year":"2020","unstructured":"Moinzadeh P, Kuhr K, Siegert E, et al. Scleroderma renal crisis: risk factors for an increasingly rare organ complication. J Rheumatol. 2020;47:241\u20138.","journal-title":"J Rheumatol"},{"key":"1962_CR48","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12016-022-08945-x","volume":"64","author":"A Cole","year":"2023","unstructured":"Cole A, Ong VH, Denton CP. Renal disease and systemic sclerosis: an update on scleroderma renal crisis. Clin Rev Allergy Immunol. 2023;64:378\u201391.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"Suppl 100","key":"1962_CR49","first-page":"122","volume":"34","author":"CB Chighizola","year":"2016","unstructured":"Chighizola CB, Pregnolato F, Meroni PL, Denton CP, Ong VH. N-terminal pro brain natriuretic peptide as predictor of outcome in scleroderma renal crisis. Clin Exp Rheumatol. 2016;34(Suppl 100):122\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"1962_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02548-1","volume":"23","author":"S Jaafar","year":"2021","unstructured":"Jaafar S, Lescoat A, Huang S, et al. Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthritis Res Ther. 2021;23:170.","journal-title":"Arthritis Res Ther"},{"key":"1962_CR51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10067-013-2422-0","volume":"33","author":"M Iudici","year":"2014","unstructured":"Iudici M, Fasano S, Iacono D, Russo B, Cuomo G, Valentini G. Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries. Clin Rheumatol. 2014;33:153\u201364.","journal-title":"Clin Rheumatol"},{"key":"1962_CR52","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327\u201339.","journal-title":"Ann Rheum Dis"},{"key":"1962_CR53","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","volume":"84","author":"F Del Galdo","year":"2025","unstructured":"Del Galdo F, Lescoat A, Conaghan PG, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2025;84:29\u201340.","journal-title":"Ann Rheum Dis"},{"key":"1962_CR54","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","volume":"55","author":"CP Denton","year":"2016","unstructured":"Denton CP, Hughes M, Gak N, et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford). 2016;55:1906\u201310.","journal-title":"Rheumatology (Oxford)"},{"key":"1962_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-2140-3","volume":"22","author":"S Panopoulos","year":"2020","unstructured":"Panopoulos S, Chatzidionysiou \u039a, Tektonidou MG, et al. Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. Arthritis Res Ther. 2020;22:56.","journal-title":"Arthritis Res Ther"},{"key":"1962_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1735-4","volume":"20","author":"S Hu","year":"2018","unstructured":"Hu S, Hou Y, Wang Q, Li M, Xu D, Zeng X. Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China. Arthritis Res Ther. 2018;20:235.","journal-title":"Arthritis Res Ther"},{"key":"1962_CR57","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A Fern\u00e1ndez-Codina","year":"2018","unstructured":"Fern\u00e1ndez-Codina A, Walker KM, Pope JE, Scleroderma algorithm Group. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 2018;70:1820\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"1962_CR58","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","volume":"35","author":"FH n den Hoogen","year":"1996","unstructured":"n den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35:364\u201372.","journal-title":"Br J Rheumatol"},{"key":"1962_CR59","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s10067-019-04784-y","volume":"39","author":"L Yang","year":"2020","unstructured":"Yang L, Wang Q, Hou Y, et al. The Chinese herb tripterygium wilfordii Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR center. Clin Rheumatol. 2020;39:813\u201321.","journal-title":"Clin Rheumatol"},{"key":"1962_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.691031","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Zhu W, He H, et al. Efficacy and safety of tripterygium wilfordii Hook. F for connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis. Front Pharmacol. 2021;12:691031.","journal-title":"Front Pharmacol"},{"key":"1962_CR61","doi-asserted-by":"publisher","first-page":"8215","DOI":"10.21037\/apm-21-256","volume":"10","author":"Y Luo","year":"2021","unstructured":"Luo Y, Zhang Y, Kuai L, et al. Efficacy and safety of tripterygium glycosides in Sj\u00f6gren\u2019s syndrome treatment: evidence from 12 randomized controlled trials. Ann Palliat Med. 2021;10:8215\u201331.","journal-title":"Ann Palliat Med"},{"key":"1962_CR62","doi-asserted-by":"publisher","first-page":"1061738","DOI":"10.3389\/fmed.2022.1061738","volume":"9","author":"H Li","year":"2022","unstructured":"Li H, Zhang X, Yu L, et al. Comparing clinical characteristics of systemic sclerosis with or without interstitial lung disease: A cross-sectional study from a single center of the Chinese rheumatism data center. Front Med (Lausanne). 2022;9:1061738.","journal-title":"Front Med (Lausanne)"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01962-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01962-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01962-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:02:26Z","timestamp":1765422146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01962-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1962"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01962-y","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Medical Ethics Committee of PUMCH (Beijing, China) (I-23PJ495). Informed consent was not relevant as this was a retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"55"}}